This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
by Zacks Equity Research
Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.
5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
by Zacks Equity Research
Exelixis (EXEL) lead drug, Cabometyx continues to perform well.
Bristol-Myers Squibb (BMY) Stock Moves -0.04%: What You Should Know
by Zacks Equity Research
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $47.97, marking a -0.04% move from the previous day.
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
by Kinjel Shah
Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
Bristol-Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Bristol-Myers Squibb (BMY) closed the most recent trading day at $47.99, moving -0.87% from the previous trading session.
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
by Zacks Equity Research
Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.
Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo
by Zacks Equity Research
Lilly (LLY) looks to acquire small cancer biotech, Loxo Oncology, to expand its pipeline into targeted cancer therapies.
Crowded Cancer Space Triggers Big M&A Deals: More in Store?
by Zacks Equity Research
Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Merck, Pfizer and AbbVie
AbbVie (ABBV) Inks Immunotherapy Deal with Private Biotech
by Zacks Equity Research
AbbVie (ABBV) inks deal with Tizona Therapeutics, to develop and commercialize CD39-targeted therapeutics, including TTX-030, which is a first-in-class antibody for the treatment of cancer.
Manufacturing, Apple, & Jobs: This Week's Top Market Stories
by Ryan McQueeney
Ryan McQueeney and Maddy Johnson discuss the ISM manufacturing index, the latest jobs report, Apple's profit warning, and a major merger deal in the biotech industry.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
by Sweta Killa
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Company News For Jan 4, 2019
by Zacks Equity Research
Companies in the news are: BMY, CELG, DAL, TRCO and ATRA
Bristol-Myers to Acquire Leading Biotech Celgene for $74B
by Zacks Equity Research
Bristol-Myers (BMY) announces an agreement to acquire leading biotech player, Celgene, for a whopping $74 billion.
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
by Zacks Equity Research
Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.
Bristol-Myers' (BMY) Sprycel Gets FDA Nod for Label Expansion
by Zacks.com
Bristol-Myers' (BMY) obtains FDA approval for the label expansion of leukemia drug Sprycel to include pediatric population.
Big News Day: Apple, New Jobs, Celgene & More
by Mark Vickery
Apple guides drastically lower, taking stock indexes down with it. Plus, Bristol buys Celgene for &4 billion, and new jobs data is mixed.
Horizon Pharma (HZNP) Up 28% on Business Expansion Strategy
by Zacks Equity Research
Horizon Pharma's (HZNP) share price increases about 28% based on its business expansion plan and acquisitions.
Portola Up as Large-Scale Andexxa Production Gets FDA Nod
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) announces FDA approval for large-scale Generation II manufacturing process for Andexxa to support commercial launch expected this month.
Heron Gains on Priority Review Designation for Pain Drug
by Zacks Equity Research
Heron (HRTX) soars after the FDA accepted the company's NDA for pain drug, HTX-011, and granted Priority Review designation to the application.